Showing results (121-130 of 517) with videos related to

Sort By:
Pageof 52
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2025
Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical PracticeSophia S Li, Anita D'Souza, Suzanne Lentzsch, et al.
Plos One|November 28, 2012
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathwayVijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, et al.
Nucleic Acids Research|December 31, 2005
ProTherm and ProNIT: thermodynamic databases for proteins and protein-nucleic acid interactionsM D Shaji Kumar, K Abdulla Bava, M Michael Gromiha, et al.
Blood Cancer Journal|May 25, 2026
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination SurveyShaji Kumar, David Murray, Dirk R Larson, et al.
American Journal of Hematology|March 18, 2021
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic reviewGhulam Rehman Mohyuddin, Kelly Koehn, Al-Ola Abdallah, et al.
The Oncologist|April 1, 2023
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed MyelomaRafael Fonseca, Thierry Facon, Mahmoud Hashim, et al.
Clinical Nephrology|December 19, 2017
High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathyNicola Lepori, Wisit Cheungpasitporn, Sanjeev Sethi, et al.
The New England Journal of Medicine|January 18, 2018
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined SignificanceRobert A Kyle, Dirk R Larson, Terry M Therneau, et al.
Leukemia & Lymphoma|March 15, 2022
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparisonKatja Weisel, Ajay K Nooka, Evangelos Terpos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 8, 2003
An oncolytic measles virus engineered to enter cells through the CD20 antigenAmanda D Bucheit, Shaji Kumar, Deanna M Grote, et al.
Pageof 52